Both experience excess skin laxity, reduced elasticity, and devolumization
See our full fatigue section
Multiple GLP-1R agonists have entered into clinical trials, such as semaglutide, progressing to approval
*Correspondence: Kevin Graeme Murphy, Section of Investigative Medicine, Department of Medicine, Imperial College London, Hammersmith Hospital, 6th Floor Commonwealth Building, Du Cane Road, London W12 0NN, UK, [email protected] Specialty section: This article was submitted to Neuroenergetics, Nutrition and Brain Health, a section of the journal Frontiers in Nutrition Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers